BIDU

Prezzo Baidu

Closed
BIDU
$114,41
+$3,06(+2,74%)

*Data last updated: 2026-04-08 00:43 (UTC+8)

As of 2026-04-08 00:43, Baidu (BIDU) is priced at $114,41, with a total market cap of $37,63B, a P/E ratio of 77,69, and a dividend yield of 0,00%. Today, the stock price fluctuated between $108,83 and $115,02. The current price is 5,12% above the day's low and 0,53% below the day's high, with a trading volume of 678,44K. Over the past 52 weeks, BIDU has traded between $81,17 to $165,30, and the current price is -30,78% away from the 52-week high.

BIDU Key Stats

Yesterday's Close$111,28
Market Cap$37,63B
Volume678,44K
P/E Ratio77,69
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)1,70
Net Income (FY)$5,58B
Revenue (FY)$129,07B
Earnings Date2026-05-20
EPS Estimate1,68
Revenue Estimate$4,58B
Shares Outstanding338,20M
Beta (1Y)0.431

About BIDU

Baidu, Inc. provides online marketing and cloud services through an internet platform in the People's Republic of China. It operates in two segments, Baidu Core and iQIYI. The Baidu Core segment offers search-based, feed-based, and other online marketing services; cloud services; and products and other services from AI initiatives. This segment also operates Haokan, a user generated and professionally produced short videos platform. The iQIYI segment operates an online entertainment video platform that offers original, professionally produced, and partner-generated content. The company was incorporated in 2000 and is headquartered in Beijing, the People's Republic of China.
SectorCommunication Services
IndustryInternet Content & Information
CEOYanhong Li
HeadquartersBeijing,None,CN
Official Websitehttps://ir.baidu.com
Employees (FY)18,60K
Average Revenue (1Y)$6,93M
Net Income per Employee$300,48K

Baidu (BIDU) FAQ

What's the stock price of Baidu (BIDU) today?

x
Baidu (BIDU) is currently trading at $114,41, with a 24h change of +2,74%. The 52-week trading range is $81,17–$165,30.

What are the 52-week high and low prices for Baidu (BIDU)?

x

What is the price-to-earnings (P/E) ratio of Baidu (BIDU)? What does it indicate?

x

What is the market cap of Baidu (BIDU)?

x

What is the most recent quarterly earnings per share (EPS) for Baidu (BIDU)?

x

Should you buy or sell Baidu (BIDU) now?

x

What factors can affect the stock price of Baidu (BIDU)?

x

How to buy Baidu (BIDU) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Baidu (BIDU)

GateUser-bd883c58

GateUser-bd883c58

03-30 11:50
问AI · 信达生物盈利转正如何折射创新药行业新周期? **21世纪经济报道记者季媛媛** 3月26日,港股创新药龙头信达生物(01801.HK)交出了年度成绩单。财报数据显示,公司首次实现国际财务报告准则(IFRS)计量下的全年盈利,净利润达8.14亿元。同期,公司总收入突破130亿元大关,达到130.42亿元,同比增长38.4%,其中核心的产品收入达118.96亿元,同比增长44.6%。 在经历了一段时间的行业寒冬与估值重构后,这份盈利“转正”的成绩单,不仅为信达生物自身的发展注入了强心剂,更向市场传递出一个积极信号:中国头部的创新药企,正逐步跨越“投入期”,进入“收获期”。然而,在医保控费常态化、行业竞争白热化、国际化壁垒高企的多重挑战下,信达生物的突围路径,也为整个创新药行业提供了观察的范本。 有券商医药行业分析师对21世纪经济报道记者表示,在融资环境趋紧的背景下,信达通过“规模效应+精益运营”实现盈利,为持续的研发投入和BD合作腾挪出空间,避免了“有增长无质量”的困境。特别在PD-1赛道增长放缓后,信达凭借玛仕度肽在减重/代谢领域打开了新的增长曲线,有效分散了单一品种的风险,增强了业绩的稳定性和抗周期性。 “2025年,信达与武田、礼来等跨国药企达成多项重磅合作,总交易额超220亿美元。特别是与武田的‘联合开发+联合商业化’模式,标志着中国药企正从‘卖青苗’升级为‘全球合伙人’,有望分享更高的全球价值链收益。”该分析师说。 **基本盘迎变** 信达生物2025年业绩的最大亮点,在于其业务结构实现了根本性的优化。长期以来,以信迪利单抗(达伯舒®)为代表的肿瘤产品线是公司的绝对支柱。而在2025年,以减重/糖尿病药物玛仕度肽(信尔美®)、自免药物匹康奇拜单抗(信美悦®)等为代表的综合产品线,已从“蓄势”走向“爆发”,成为驱动增长的“第二引擎”。 财报显示,公司综合产品线的快速扩张,是产品收入同比增长44.6%的关键驱动力。信达生物董事会主席兼首席执行官俞德超博士在业绩会上将此概括为“肿瘤和慢病双轮驱动的发展格局”。这意味着,公司不再仅仅依赖单一治疗领域或单一重磅产品,而是构建了更为均衡、抗风险能力更强的商业化矩阵。 这一转变的商业逻辑清晰可见:肿瘤领域虽然市场空间巨大,但竞争也最为激烈,且受医保谈判影响价格压力显著。根据IQVIA发布的数据,2025年下半年肿瘤治疗免疫类药物PD-(L)1的市场患者使用占比仍然保持稳步增长。与2025年上半年相比,增长率为6.9%;与2024年下半年同比,有11.2%的增长率;环比和同比都相较25年上半年有所提高,患者使用占比保持持续上升趋势。 2025年下半年至今(截至2026年3月中旬),PD-(L)1靶点相关新获批上市产品中,瑞拉芙普α(国内商品名:艾泽利)是全球首个获批上市的PD-L1/TGF-β双特异性抗体。该药于2026年1月获国家药品监督管理局批准上市,适应症为胃及胃食管结合部腺癌的一线治疗。另外,有PD-(L)1类产品的新剂型获批上市,阿替利珠单抗(泰圣奇)皮下注射在2025年11月获批上市(注射剂上市时间为2020年2月),为首个MNC PD-L1皮下注射制剂。至此,目前共有24个PD-(L)1产品在国内获批上市。在已上市产品中,适应症/制剂扩展方面,自2025年下半年至今,已有7个产品获得新适应症批准。 如此可见,肿瘤产品市场竞争进入白热化。而慢病领域,尤其是代谢、自身免疫等,拥有庞大的患者基数、长期用药需求以及更高的市场渗透潜力。以玛仕度肽为例,作为全球首款GCG/GLP-1双受体激动剂,其9mg高剂量适应症的上市申请已获受理。在中国减重市场渗透率远低于欧美(美国GLP-1渗透率超10%,中国不足1%)的背景下,这一产品的放量空间极具想象力。 信达生物在业绩会上透露,2025年信达生物已有18款产品上市,其中12款纳入国家医保目录(NRDL),强大的商业化能力与广泛的市场覆盖,为其稳定贡献了超过百亿元的营收底盘。从首个产品上市到营收规模突破百亿元,信达仅用了约7年时间,这在国内本土药企中速度居前,也为其持续投入研发和国际化提供了“造血”能力。 **提升商业化效率** 如果说“双轮驱动”是收入端的成功,那么首次实现全年盈利,则更多体现了公司在运营效率与成本控制上的进步。2025年,信达生物Non-IFRS净利润达17.23亿元,同比增长419.6%。 首席财务官由飞在业绩会上表示,盈利的实现得益于产品快速增长带来的规模效应,以及公司持续秉持的精益经营理念。一个显著的数据是,在综合管线新产品密集上市的同时,公司的销售费用率却实现了同比下降。这表明,随着品牌认知度的提升和商业化团队的成熟,新产品的市场推广效率正在提高。 同时,公司对研发费用的管控也日益精细化。由飞指出,未来国内研发费用将保持在20-30亿人民币的区间,聚焦于现有管线的生命周期管理、早期研究以及即将上市产品的临床开发,同时充分利用中国的临床效率优势,高效推进早期临床和概念验证(PoC)。截至2025年底,信达生物手握超过35亿美元的现金储备,这笔丰厚的“家底”为其后续管线的研发推进和国际化的深度布局提供了坚实的“护城河”。 前述分析师也指出, 随着创新药加速上市,医保控费和集采将进入深水区。未来竞争的核心是商业化效率和成本控制能力。信达约80%的毛利率和优化的费用率为其应对价格压力提供了缓冲。 对于中国创新药企而言,国内市场是根基,但欧美发达国家市场才是利润和价值的“高地”。俞德超博士在业绩会上直言:“在中国医药市场,药品销售额约占全球的8%-9%,但行业利润仅约3%。要成为国际一流企业,前提是进入欧美发达市场。” 根据公开信息披露,2025年,信达生物的国际化进程从“战略储备”阶段,正式迈入“价值兑现”阶段。短短一年内,公司三项核心资产——IBI363(PD-1/IL-2α-bias)、IBI343(CLDN18.2 ADC)和IBI324已推进至或即将进入全球注册性临床研究。据合作伙伴估算,这三个产品的潜在全球市场规模合计超过600亿美元。 与此同时,公司在对外授权合作(BD)上也取得了突破性进展。与武田制药达成的全球战略合作,首付款高达12亿美元,潜在交易总额超百亿美元;与老搭档礼来的第七次合作,以及将DLL3 ADC授权给罗氏,均有力验证了其创新平台的全球竞争力。据统计,信达生物过去一年达成的合作总金额超过220亿美元,占中国创新药同期授权交易总金额的10%以上。 这些合作不仅仅是财务上的巨大收益,更关键的是,通过整合武田、礼来、罗氏等全球巨头的临床开发经验、监管沟通能力和商业化网络,信达生物正在快速学习并构建自身独立进行全球药物研发的能力。正如俞德超所期望的,未来公司将实现从“合作开发”到“独立自主开展全球药物研发”的跨越。 **打开价值天花板** 将目光从信达生物身上移开,置于整个中国创新药行业的大背景下,不难发现,信达的路径正是行业头部企业“突围”的缩影。 经历了前几年的资本狂热和泡沫期,中国创新药行业正步入一个更加理性的发展新周期。在这个周期里,单纯的“Me-too”或快速跟进策略已难以为继。企业面临着三大核心挑战:医保支付端的压力。国家医保目录谈判常态化,大幅压缩了创新药在国内市场的价格空间和利润回报周期;同质化竞争的困局。PD-1、Claudin 18.2 ADC、GLP-1等热门靶点扎堆,导致商业化竞争激烈;国际化的高门槛。欧美市场虽然利润丰厚,但监管标准严苛、临床开发成本高昂、商业化体系复杂,对企业的综合实力提出了极高要求。 面对挑战,头部药企正在探索出两条核心突围路径。一方面,深耕差异化创新,构筑技术壁垒。例如, 信达生物提出的“IO+ADC”新一代战略,以及玛仕度肽独特的GCG/GLP-1双靶点设计,都是差异化的体现。通过布局First-in-class或Best-in-class的分子,才能在激烈的市场竞争中占据定价权和品牌优势。 信达生物肿瘤管线首席研发官周辉博士在业绩会上透露,在肿瘤领域,公司还有IBI363(PD-1/IL-2)、IBI354(针对HER2低表达)以及一些全球首创的双抗分子有望推进全球临床。在代谢、免疫领域,每周一次的口服小分子、对标杜匹鲁单抗的下一代产品等,都展现了其从“跟跑”到“并跑”乃至“领跑”的雄心。 另一方面,坚定全球化战略,打开价值天花板。 这不仅是将产品卖到海外,更是要构建全球化的研发、注册、商业化能力。信达披露,已在美国组建了超百人的团队,同时通过与全球巨头的合作,汲取养分,加速成长。目标是到2030年,至少有5个分子进入全球国际多中心临床注册研究。这一目标一旦实现,将彻底打开公司的成长空间和估值体系。 然而,挑战同样不容忽视。国内方面,医保支付端的压力依然存在,例如,玛仕度肽在2026年面临同类产品降价后的市场竞争。国际方面,虽然管线推进顺利,但全球多中心临床的高昂费用、复杂的患者入组以及FDA等监管机构的审批不确定性,仍是需要跨越的障碍。 对于2026年,信达生物充满信心。公司重申了2027年实现200亿人民币收入的目标,并预计2026年仍将保持高速的收入增长。未来,信达能否将目前的“双轮驱动”优势转化为“全球一流”的终极地位,将取决于其国际化管线能否顺利开花结果,以及能否持续证明其作为全球性生物制药企业的研发和商业价值。对于整个中国创新药行业而言,信达生物的探索之路,无疑提供了一个值得持续观察和借鉴的范本。
0
0
0
0
FomoAnxiety

FomoAnxiety

04-02 13:45
Alibaba BABA -1.38% ▼ , the Chinese e-commerce and cloud company, launched its new Qwen3.6-Plus AI model, aiming to strengthen its position in the fast-growing AI race. The update highlights better coding and task handling, but investor reaction remained muted amid intense competition in China’s AI market. ### End of Quarter Sale - 50% Off TipRanks * Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions * Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks **New Model Targets Smarter Coding and Faster Work** ---------------------------------------------------- Alibaba said Qwen3.6-Plus brings a clear improvement in coding tasks. It can handle everything from basic web building to more complex, project-level problems. The model is available through Alibaba Cloud’s Model Studio and can be used via API. It also works with coding tools like OpenClaw, Claude Code, and Qwen Code, making it easier for developers to build and test programs. The company added that the model is better at understanding text, images, and video together. This helps it take on more real-world tasks and provides more accurate results. Alibaba noted that this update builds on user feedback from Qwen3.5, which was released in February. The focus this time is on making the model more stable and more useful for daily developer work. **Rising Competition Keeps Pressure on** ---------------------------------------- Alibaba’s AI push comes at a time when competition in China is getting intense. Companies like ByteDance, Baidu BIDU +0.43% ▲ , and DeepSeek are all launching similar models and cutting prices to gain market share. This makes it harder for any one player to stand out, even with strong updates. Still, Alibaba’s latest move shows it is not slowing down. The company is clearly betting that AI will be a key driver of future growth, even as near-term pressure on the stock remains. **Is Alibaba Stock a Buy Now?**  -------------------------------- Wall Street remains constructive on the stock. Alibaba carries a Strong Buy consensus rating based on 16 Buy ratings and two Holds over the past three months. The average BABA price target stands at $187.23, suggesting roughly 51.32% upside from current levels. Disclaimer & DisclosureReport an Issue
0
0
0
0